2014
DOI: 10.1111/xen.12124
|View full text |Cite
|
Sign up to set email alerts
|

Cloning and expression of porcine β1,4 N‐acetylgalactosaminyl transferase encoding a new xenoreactive antigen

Abstract: Background Xenograft rejection of pigs organs with an engineered mutation in the GGTA-1 gene (GTKO) remains a predominantly antibody mediated process which is directed to a variety of non-Gal protein and carbohydrate antigens. We previously used an expression library screening strategy to identify six porcine endothelial cell cDNAs which encode pig antigens that bind to IgG induced after pig-to-primate cardiac xenotransplantation. One of these gene products was a glycosyltrasnferase with homology to the bovine… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
95
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 128 publications
(96 citation statements)
references
References 43 publications
1
95
0
Order By: Relevance
“…−/− pig endothelial cells with sera from primates that had rejected GGTA1 −/− pig hearts [24,25]. Expression of B4GALNT2 in human cells significantly increased antibodydependent complement-mediated lysis when these cells were challenged with serum from pig-to-baboon cardiac xenotransplantation sensitized recipient serum [25] while its deletion in pig PBMCs efficiently reduced human IgG and IgM binding and decreased human anti-porcine cytotoxicity [26,27].…”
Section: Modification Of Donor Pigs To Mitigate the Immunementioning
confidence: 99%
See 1 more Smart Citation
“…−/− pig endothelial cells with sera from primates that had rejected GGTA1 −/− pig hearts [24,25]. Expression of B4GALNT2 in human cells significantly increased antibodydependent complement-mediated lysis when these cells were challenged with serum from pig-to-baboon cardiac xenotransplantation sensitized recipient serum [25] while its deletion in pig PBMCs efficiently reduced human IgG and IgM binding and decreased human anti-porcine cytotoxicity [26,27].…”
Section: Modification Of Donor Pigs To Mitigate the Immunementioning
confidence: 99%
“…Expression of B4GALNT2 in human cells significantly increased antibodydependent complement-mediated lysis when these cells were challenged with serum from pig-to-baboon cardiac xenotransplantation sensitized recipient serum [25] while its deletion in pig PBMCs efficiently reduced human IgG and IgM binding and decreased human anti-porcine cytotoxicity [26,27]. The fact that a strong humoral response was detected in nonhuman primates receiving alginate-encapsulated islets especially against αGal [28,29] further emphasizes the necessity to use GGTA1-KO pigs as a background for other genetic modifications.…”
Section: Modification Of Donor Pigs To Mitigate the Immunementioning
confidence: 99%
“…Although less is known about B4GALNT2, it is thought to play a part in the nonGal immune response after pig-to-primate xenotransplantation. Porcine B4GALNT2 was shown to cause antibody binding and complement mediated lysis in the presence of primate serum after pig-to-primate cardiac xenotransplantation using GTKO donors [37] . Preliminary data suggest that, primate antibody binding is reduced when B4GALNT2 is deleted from the donor pig.…”
Section: Hyperacute Rejection: Non-galmentioning
confidence: 96%
“…Two non-Gal antigens have received particular attention: N-glycolylneuraminic acid (NeuGc) also known as Hanganutziu-Deicher, and β1,4 N-acetylgalactosaminyltransferase (B4GALNT2) [35][36][37] . Similarly to Gal, NeuGc is not expressed in humans (nor in New World monkeys) but it is in most other species.…”
Section: Hyperacute Rejection: Non-galmentioning
confidence: 99%
“…Two nonGal antigens have subsequently been identified, namely N-glycolylneuraminic acid [9] and Sda (β4GalNT2) [10]. When expression of one or both of these has been deleted from the organ-source pig by knockout technology, antibody binding has been reduced further [11, 12].…”
Section: Pathobiological Barriersmentioning
confidence: 99%